IGXT ($46 M) 2 NDA Submission within 2 months this
Post# of 83
(Total Views: 733)
Posted On: 06/07/2017 2:30:28 PM
IGXT ($46 M) 2 NDA Submission within 2 months this will make IGXT as one of the most attractive and underpriced fda play you can get at this time .
Market Cap $46 Million
Cash untill 2021+ (including convertible debt)
Price: 0.70
NDA submission for tadalafil in June or July
NDA resubmission for Rizaport in early Q3
Partnership for Tadalafil in 2H 2017
Most people still not realize the signifance of this news below ..Tadalafil could be up to 2 years on market before the generics enter the Market THATS MEGA NEWS for Intelgenx they will earn a lot of money .
http://www.biotuesdays.com/features/2017/5/11...oral-films
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020 . IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Market Cap $46 Million
Cash untill 2021+ (including convertible debt)
Price: 0.70
NDA submission for tadalafil in June or July
NDA resubmission for Rizaport in early Q3
Partnership for Tadalafil in 2H 2017
Most people still not realize the signifance of this news below ..Tadalafil could be up to 2 years on market before the generics enter the Market THATS MEGA NEWS for Intelgenx they will earn a lot of money .
http://www.biotuesdays.com/features/2017/5/11...oral-films
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020 . IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
(0)
(0)